Clinical trials: Macular Neovascularisation
AMD, Age-related Macular Degeneration
Resveratrol for Exudative Age-Related Macular Degeneration
This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.
- Conditions
- AMD, Age-related Macular Degeneration, Choroidal Neovascularisation
- Trial name
- AGED (NCT02625376)
- Testing
- Resvega, Trans-Resveratrol
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Poitiers University Hospital
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Macular Degeneration, Choroidal Neovascularization
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD).
- Trial name
- NCT01021956
- Testing
- STAKEL
- Where
- 4 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Steba Biotech S.A.
Retinal Diseases, Choroidal Disease
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly…
- Conditions
- Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy
- Trial name
- NCT06918028
- Testing
- With fundus diseases, Without fundus diseases
- Where
- China
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.
- Trial name
- CyPov (NCT02976194)
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Pusan National University Hospital
Choroidal Neovascularization, Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT00305630
- Testing
- Periocular injection of triamcinolone acetonide 40mg
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Age-related Macular Degeneration
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
- Trial name
- NCT00251459
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Branch Retinal Vein Occlusion
Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion
The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.
- Trial name
- NCT00370266
- Testing
- Triamcinolone
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Myopic Macular Haemorrhages
Myopic Macular Haemorrhages
1. To identify the underlying causes of macular haemorrhages in patients with high myopia 2. In the eyes found to have macular haemorrhages secondary to choroidal neovascularisation, we hope to identify the risk factors for the…
- Trial name
- NCT00345228
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore National Eye Centre
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration, Choroidal Neovascularization
Efficacy of Retreatments With Intravitreal Bevacizumab
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual…
- Trial name
- NCT00406744
- Testing
- Intravitreal injection of Bevacizumab
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Macular Degeneration
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy, or PDT…
- Trial name
- NCT00043680
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Eye Institute (NEI)
Age Related Macular Degeneration, Choroidal Neovascularization
Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD).
- Trial name
- NCT01336907
- Where
- France
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Macular Degeneration, Choroidal Neovascularization
Phase II/III Study of Anti-VEGF in Neovascular AMD
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
- Trial name
- NCT00021736
- Testing
- EYE001 anti-VEGF aptamer
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals